Risk Factors and Predictors of Torsade de Pointes Ventricular Tachycardia in Patients With Left Ventricular Systolic Dysfunction Receiving Dofetilide

American Journal of Cardiology

Volumn 100, Issue 5, 2007, Pages 876-880

  Pedersen, Henriette Sloth ^a   Elming, Hanne ^b   Seibæk, Marie ^c   Burchardt, Hans ^d   Brendorp, Bente ^c   Torp Pedersen, Christian ^d   Køber, Lars ^c  

^a FREDERIKSBERG HOSPITAL   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

^c Mental Health Services CPH   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE TITRATION; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; QT DISPERSION; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TORSADE DES POINTES;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIAC OUTPUT, LOW; CAUSE OF DEATH; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FORECASTING; HEART ARREST; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHENETHYLAMINES; PLACEBOS; POTASSIUM CHANNEL BLOCKERS; RISK FACTORS; SEX FACTORS; SULFONAMIDES; TIME FACTORS; TORSADES DE POINTES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34547939857     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.04.020     Document Type: Article

References (24)

1. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., Tavazzi L., and Smiseth O.A. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 26 (2005) 1115-1140
2. Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldmanmd A.M., Francis G.S., Ganiats T.G., Goldstein S., Gregoratos G., Jessup M.L., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure). Circulation 104 (2001) 2996-3007
3. Piepoli M., Villani G.Q., Ponikowski P., Wright A., Flather M.D., and Coats A.J.S. Overview and meta-analysis of randomised trials of amidarone in chronic heart failure. Int J Cardiol 66 (1998) 1-10
4. Chaudhry G.M., and Haffajee C.I. Antiarrhythmic agents and proarrhythmia. Cri Care Med 28 suppl (2000) N158-N164
5. Camm A.J., and Yap Y.G. What should we expect from the next generation of antiarrhythmic drugs?. J Cardiovasc Electrophysiol 10 (1999) 307-317
6. Elming H., Brendorp B., Pedersen O.D., Køber L., and Torp-Pedersen C. Dofetilide: a new drug to control cardiac arrhythmia. Expert Opin 4 (2003) 1-13
7. Køber L., Bloch-Thomsen P.E., Møller M., Torp-Pedersen C., Carlsen J., Sandøe E., Egstrup K., Agner E., Videbæk J., Marchant B., and Camm A.J. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 356 (2000) 2052-2058
8. Torp-Pedersen C., Møller M., Bloch-Thomsen P.E., Køber L., Sandøe E., Egstrup K., Agner E., Carlsen J., Videbæk J., Marchant B., and Camm A.J. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 341 (1999) 857-865
9. Schiller N., Shah P., Crawford M., DeMaria A., Devereux R., Feigenbaum H., Gutgesell H., Reichek N., Sahn D., and Schnittger I. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
10. Berning J., Nielsen J.R., Launbjerg J., Fogh J., Mickley H., and Andersen P. Rapid estimation of left ventricular ejection fraction in acute myocardial infraction by echocardiographic wall motion analysis. Cardiology 80 (1992) 257-266
11. Domanski M.J., Krause-Steinrauf H., Massie B.M., Deedwania P., Follmann D., Kovar D., Murray D., Oren R., Rosenberg Y., Young J., Zile M., and Eichhorn E. A comparative analysis of the results from 4 rrials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 9 (2003) 354-363
12. Crockcroft D., and Gault M. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
13. Brendorp B., Elming H., Jun L., Køber L., Malik M., Jensen G.B., Torp-Pedersen C., and Group D.S. QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation 103 (2001) 1422-1427
14. Bedner M.M., Harrigan E.P., and Ruskin J.N. Torsade de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 89 (2002) 1316-1319
15. Gowda R.M., Khan I.A., Wilbur S.L., Vasavada B.C., and Sacchi T.J. Torsade de pointes: the clinical considerations. Int J Cardiol 96 (2004) 1-6
16. Makkar R.R., Fromm B.S., Steinman R.T., Meissner M.D., and Lehmann M.H. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA 270 (1993) 2590-2597
17. Hohnloser S.H. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am J Cardiol 8A suppl (1997) 82G-89G
18. Lehmann M.H., Timothy K.W., Frankovich D., Fromm B.S., Keating M., Locati E.H., Taggart R.T., Towbin J.A., Moss A.J., Schwartz P.J., and Vincent M. Age-gender influence on the rate-corrected QT interval and the QT-heart rate relation in families with genotypically characterized long QT syndrome. J Am Coll Cardiol 29 (1997) 93-99
19. Peters R., and Gold M. The influence of gender on arrhythmias. Cardiol Rev 12 (2004) 97-105
20. Wolbrette D., Nacccarelli G., Curtis A., Lehmann M., and Kadish A. Gender differences in arrhythmias. Clin Cardiol 2 (2002) 39-56
21. James A.F., and Hancox J.C. Sex, drugs and arrhythmia: are gender differences in risk of torsade de pointes simply a matter of testosterone?. Cardiovasc Res 57 (2003) 1-4
22. Abi-Gerges N., Philp K., Pollard C., Wakefield I., Hammond T.G., and Valentin J.-P. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsade de Pointes. Fundam Clin Pharmacol 18 (2004) 139-151
23. Wolbrette D.L. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol 91 suppl (2003) 39D-44D
24. Pedersen O.D., Bagger H., Keller N., Marchant B., Køber L., and Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality On Dofetilide (DIAMOND) Substudy. Circulation 104 (2001) 292-296